樂普醫療(300003.SZ)完成發行8億元超短期融資券
格隆匯11月22日丨樂普醫療(300003.SZ)公佈,公司於2019年11月21日完成2019年度第二期超短期融資券人民幣8億元的發行。公司在嚴控負債規模和持續、有效降低資產負債率的前提下,有效調整優化公司負債結構,此次進行的超短期融資將完成對到期融資資金的置換。至此,公司年內債券發行計劃已全部完成。此次發行結果説明如下:債券簡稱“19樂普SCP002”;債券代碼“011902721”;期限180日;實際發行總額8億元;發行利率4.45%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.